BC Week In Review | Mar 8, 2010
Company News

Adamis, Colby, La Jolla Pharmaceutical deal

Adamis received exclusive rights to Colby's CPC-300 , a small molecule signal transduction inhibitor in preclinical testing to treat prostate cancer. Colby received 1 million shares of Adamis, which are valued at $410,000 based on Adamis'...
Items per page:
1 - 1 of 1